Edition:
United Kingdom

Opiant Pharmaceuticals Inc (OPNT.OQ)

OPNT.OQ on NASDAQ Stock Exchange Capital Market

19.84USD
20 Apr 2018
Change (% chg)

$-0.66 (-3.22%)
Prev Close
$20.50
Open
$20.30
Day's High
$20.30
Day's Low
$19.84
Volume
1,151
Avg. Vol
12,722
52-wk High
$51.90
52-wk Low
$17.01

Chart for

About

Opiant Pharmaceuticals, Inc., formerly Lightlake Therapeutics, Inc., is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was... (more)
No analyst recommendations are available for .

Overall

Beta: -0.18
Market Cap(Mil.): $50.35
Shares Outstanding(Mil.): 2.54
Dividend: --
Yield (%): --

Financials

  OPNT.OQ Industry Sector
P/E (TTM): -- 31.01 33.60
EPS (TTM): -1.41 -- --
ROI: -18.23 13.60 13.19
ROE: -22.04 15.26 15.00

BRIEF-Opiant Pharma Reports Financial Results

* OPIANT PHARMACEUTICALS, INC. REPORTS FINANCIAL RESULTS FOR AUGUST 1, 2017, THROUGH DECEMBER 31, 2017, AND PROVIDES CORPORATE UPDATE Source text for Eikon: Further company coverage:

07 Mar 2018

BRIEF-Opiant Pharma Says Teva Filed ANDA With FDA For Marketing Approval Of Generic Version Of Narcan 2 Mg/Spray

* OPIANT PHARMACEUTICALS SAYS ON FEB 27, CO AND ADAPT PHARMA OPERATIONS LIMITED RECEIVED NOTICE FROM TEVA PHARMACEUTICALS USA INC - SEC FILING

05 Mar 2018

BRIEF-Opiant Pharma Announces Positive Data From A Phase I Clinical Study Of OPNT003

* OPIANT PHARMACEUTICALS INC - ANNOUNCES POSITIVE DATA FROM A PHASE I CLINICAL STUDY OF ITS PRODUCT CANDIDATE OPNT003

12 Feb 2018

BRIEF-Opiant Pharmaceuticals To Record About $11.7 Million In Royalty

* OPIANT PHARMACEUTICALS TO RECORD APPROXIMATELY $11.7 MILLION IN ROYALTY AND MILESTONE PAYMENTS RELATED TO 2017 SALES OF NARCAN® NASAL SPRAY FOR OPIOID OVERDOSE

08 Feb 2018

BRIEF-Opiant Pharmaceuticals Receives About $5.3 Mln Of Cash From Exercise Of Outstanding Warrants

* OPIANT PHARMACEUTICALS RECEIVES APPROXIMATELY $5.3 MILLION OF CASH FROM EXERCISE OF OUTSTANDING WARRANTS Source text for Eikon: Further company coverage:

02 Jan 2018

BRIEF-Opiant Pharma Reports Financial Developments Related To Narcan Nasal Spray For Opioid Overdose

* OPIANT PHARMACEUTICALS ANNOUNCES SIGNIFICANT FINANCIAL DEVELOPMENTS RELATED TO NARCAN® NASAL SPRAY FOR OPIOID OVERDOSE

20 Dec 2017

BRIEF-Opiant Pharmaceuticals, Inc. Reports Qtrly ‍net Loss Per Common Share $2.77​

* OPIANT PHARMACEUTICALS, INC. REPORTS FISCAL FIRST QUARTER 2018 FINANCIAL RESULTS

04 Dec 2017

Earnings vs. Estimates